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Abstract
The aim of the article is to analyze the existing problems of adaptive management of manufacturing pharmaceutical com-
panies and the development of methodological support for their management.
Materials and methods. The research used methods of theoretical generalization, analysis and synthesis, synergetic ap-
proach and expert survey.
120 people were involved in the expert survey, divided into four groups: representatives of pharmaceutical manufacturing 
enterprises (30 people); representatives of pharmaceutical higher education institutions (30 people); pharmaceutical distributors rep-
resenting wholesale companies (30 people); end users (30 people).
Results. The article considers scientific and methodological approaches to improving adaptive management in the direction 
of forming competitive advantages of manufacturing pharmaceutical companies, the practical implementation of which requires busi-
ness entities determination, flexibility and adequacy in the formation of modern management strategies and tactical planning and 
operational tasks of production, economic and commercial activities. There are external and internal factors influencing the formation 
of competitive advantages of the business entity. As the internal factors we include: organizational and legal form, and business entity 
organizational structure; the level of scientific and technical development of production; level of education and qualification of staff; 
business image of the enterprise; financial reputation of the enterprise. However, no less influence on the formation of competitive 
advantages of the management of manufacturing pharmaceutical companies have external factors, which, in contrast to internal, are 
not controlled by the entity: the state of the pharmaceutical market; technologies; workforce; scientific and technical development; etc.
Conclusions. The directions of increasing the adaptive management efficiency are determined and it is concluded that the 
main criterion of efficiency is the quality of pharmaceutical products and the quality of management decisions in economic risks. 
Keywords: adaptive control, pharmaceutical manufacturing company, methodological support, drug.
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1. Introduction
Issues of competitiveness in all sectors in the national economy come to the fore, as the 
achievement of scientific and technological progress and using new technologies require busines-
ses to such a level of production that would meet global requirements and strengthen competitive 
positions in the international market. In this regard, gaining competitive advantage by economic 
entities through the improvement of existing management systems, as a more important component 
of production, economic and commercial activities, is a priority for the management of manufac-
turing pharmaceutical companies (MPhCo).
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Problems of adaptive management development of industrial enterprises were studied in 
scientific works [1, 2], questions of Quality оf Adaptive Management [3], questions of pharma-
ceutical enterprises’ management [4, 5], problems of adaptive management development of phar-
maceutical enterprises’ management [6, 7], risk-management of pharmaceutical companies [8], 
logistic ma nagement of enterprises [9, 10], macroenvironment activities of organizations [11], com-
petitiveness of companies [12, 13], etc. 
Nevertheless, the issues of methodological support for adaptive management of the MPhCo 
are not sufficiently addressed and need further development.
The aim of the study. The purpose of the article is to analyze the existing problems of adap-
tive management of MPhCo and to work out the methodological support for management.
2. Materials and methods 
The methods used in the study include methods of theoretical generalization, analysis and 
synthesis, synergetic approach and expert questioning.
120 people were involved in the expert survey in January-June 2019, divided into four 
groups: representatives of pharmaceutical manufacturing enterprises (30 people); representatives 
of the pharmaceutical industry (30 people); pharmaceutical distributors representing wholesale 
companies (30 people); end users (30 people). The object of examination are the factors influencing 
the adaptive management level of the MPhCo:
1. Introduction of innovative production technologies.
2. State financial support of the pharmaceutical industry.
3. Antitrust regulation.
4. Material, technical base and production processes updating in MPhCo.
5. Quality and availability of domestic medicines.
6. Advertising, PR, membership in associations.
7. Application of marketing and logistics tools.
8. Optimization of work with suppliers.
9. Personnel potential preservation in the MPhCo.
10. Organization, methodical support of patent work of the pharmaceutical industry enter-
prises and institutions.
The indicators were evaluated according to a 5-point system: from «1» (does not affect 
at all) to «5» (the factor influence on the adaptive management level of the MPhCo is the highest).
According to Snela-Kemeny theory, a measure of proximity was established, it allows to 
determine the distance between any pair of binary relations.
3. Results
The most effective for the national economy of Ukraine is the adaptive management of 
economic entities. Of particular importance for the adaptive management of MPhCo is the ratio of 
accuracy and speed of management response to changes in the external environment, i. e. the ratio 
of accuracy and speed of directed changes in the internal environment of the enterprise compared 
to the speed and direction of changes in the external environment [14, 15].
The main criterion for the adaptive management effectiveness of MPhCo is the pharmaceu-
tical products quality and the quality of management decisions according to economic risks.
Approaches to risk management are traditionally based on a number of organizational and 
economic measures aimed at preventing and reducing the likelihood of their occurrence. These 
include, in particular:
– availability of reliable, timely, complete information;
– control effects on MPhCo, which reduce the likelihood of environmental risk and reduce 
their negative consequences;
– use of regulatory materials to respond quickly and appropriately to the emergence of risky 
situations;
– availability of developed infrastructure (transport, storage, etc.);
– MPhCo activity insurance [16].
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In our opinion, the set of methods for managing the economic risks of the MPhCo is quite 
diverse, which is often due to the financial condition of the enterprise, the conditions of produc-
tion and economic activity and market position. In this regard, the application of an adaptive ap-
proach to economic risk management in conjunction with the tools of process, crisis and innovation 
approaches is the most acceptable for the pharmaceutical industry (Fig. 1).
Fig. 1. Economic risk management system of a manufacturing pharmaceutical company
It should be noted that the use of a combination of these methods is appropriate in case of 
need to respond quickly to abrupt changes in the external and internal environment of the MPhCo.
The complexity of production, social and other factors of the external and internal environ-
ment of the MPhCo require adequate action by management. In such circumstances, management 
decisions can be made either quickly (based on existing experience) or on the basis of thorough 
analysis and application of modelling and forecasting methods [17].
There are external and internal factors influencing the formation of competitive advantages 
of the business entity.
The internal factors we include:
– organizational and legal form and business entity organizational structure;
– the level of scientific and technical development of production;
– level of education and qualification of staff;
– business image of the enterprise;
– financial reputation of the enterprise.
However, no less influence on the formation of competitive advantages of the MPhCo have 
external factors, which, in contrast to internal, are not controlled by the entity:
– the state of the pharmaceutical market;
– technologies;
– workforce;
– scientific and technical development;
– degree of state regulation, etc.
Improving adaptive management in the direction of forming the competitive advantages of 
the MPhCo should be considered in the context of following factors of influence: socio-economic, or-
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Socio-economic factors determine the set of social relations within which the enterprise 
management system operates.
Organizational and economic factors determine the existence of institutions established in 
the form of laws or institutions, including financial, through which certain aspects of the activities 
of economic entities.
Organizational and legal factors are related to the presence or absence of the appropriate 
regulatory framework necessary for the effective implementation of the MPhCo activities.
Organizational and technical factors reflect the level of equipment and technologies deve-
lopment that necessary for the practical implementation of production, economic and commercial 
activities of the MPhCo.
Organizational and technological factors reflect the structure of making and implementing 
management decisions in the process of functioning of the MPhCo in the system of sectoral and 
national economic development [18].
The results of expert assessment of factors influencing the adaptive management level of 
the MPhCo by representatives of enterprises are given in Table 1.
Table 1




1 2 3 4 5
1 Introduction of innovative production technologies 1 3 7 7 12
2 State financial support of the pharmaceutical industry 2 5 6 9 8
3 Marketing and logistics tools application 3 5 8 8 6
4 Optimization of work with suppliers 0 0 3 11 16
5 Quality and availability of domestic medicines 2 1 6 12 9
6 Advertising, PR, membership in associations 4 8 8 6 4
7 Antitrust regulation 5 11 8 3 3
8 Personnel potential preservation in the MPhCo 0 2 7 11 10
9 Material, technical base and production processes updating in MPhCo 2 2 5 10 11
10 Organization, methodical support of patent work at enterprises and institutions of the pharmaceutical industry 4 7 8 5 6
The results of expert assessment of factors influencing the adaptive management level 
of MPhCo by representatives of pharmaceutical higher education institutions of the pharmaceutical 
industry are given in Table 2.
Table 2
The results of expert assessment of factors influencing the adaptive management level of MPhCo by 
representatives of pharmaceutical higher education institutions of the pharmaceutical industry
Criterion
Rating
1 2 3 4 5
1 Introduction of innovative production technologies 1 4 8 10 7
2 State financial support of the pharmaceutical industry 2 2 7 11 8
3 Marketing and logistics tools application 1 5 9 7 8
4 Optimization of work with suppliers 1 4 10 10 6
5 Quality and availability of domestic medicines 3 3 7 8 9
6 Advertising, PR, membership in associations 3 6 10 6 5
7 Antitrust regulation 1 5 8 9 7
8 Personnel potential preservation in the MPhCo 5 6 7 6 6
9 Material, technical base and production processes updating in MPhCo 0 4 9 8 9
10 Organization, methodical support of patent work of the pharmaceutical industry enterprises and institutions 4 8 5 7 6
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The results of expert assessment of the factors influencing the adaptive management level 
of MPhCo by pharmaceutical distributors’ representatives are given in Table 3.
Table 3
The results of expert assessment of the factors influencing the adaptive management level of MPhCo by 
pharmaceutical distributors’ representatives (wholesale companies)
Criterion
Rating
1 2 3 4 5
1 Introduction of innovative production technologies 0 1 8 11 10
2 State financial support of the pharmaceutical industry 6 10 5 5 4
3 Marketing and logistics tools application 3 3 10 6 8
4 Optimization of work with suppliers 5 5 7 6 7
5 Quality and availability of domestic medicines 1 10 11 6 2
6 Advertising, PR, membership in associations 0 5 8 8 9
7 Antitrust regulation 2 3 8 7 10
8 Personnel potential preservation in the MPhCo 2 2 9 12 5
9 Material, technical base and production processes updating in MPhCo 3 7 9 6 5
10 Organization, methodical support of patent work of the pharmaceutical industry enterprises and institutions 3 7 6 6 8
The results of expert assessment of factors influencing the adaptive management level 
of MPhCo by final users are given in Table 4.
Table 4




1 2 3 4 5
1 Introduction of innovative production technologies 0 0 1 14 15
2 State financial support of the pharmaceutical industry 4 2 8 10 6
3 Marketing and logistics tools application 4 1 7 9 9
4 Optimization of work with suppliers 1 5 10 7 7
5 Quality and availability of domestic medicines 2 8 7 8 5
6 Advertising, PR, membership in associations 3 7 6 11 3
7 Antitrust regulation 6 8 6 6 4
8 Personnel potential preservation in the MPhCo 4 6 7 8 5
9 Material, technical base and production processes updating in MPhCo 1 3 9 8 9
10 Organization, methodical support of patent work of the pharmaceutical industry enterprises and institutions 7 8 7 4 4
Therefore, it can be argued that conducting an expert assessment on a representative sam-
ple of respondents, correctly grouped, gives the correct result when using any classical methods 
of mathematical statistics.
According to the Kemeni procedure [19] an auxiliary collective ordering in each 
expert group is formed, the closest to all individual orders, which is presented as a collec-
tive (group) choice.
The results of the calculations of the elements of the loss matrix, calculated according to the 
matrices of the relations of assessment of the importance of factors influencing the level of MPhCo’ 
adaptive management of the four expert groups, are given in Table 5.
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Table 5
Loss matrix, total distances and ranking of the assessment of the importance of factors influencing the level 
of adaptive management of the MPhCo
d 1 2 3 4 5 6 7 8 9 10 C(Pv) Rank
1 4 2 1 3 2 1 2 1 2 0 18 1
2 6 4 4 5 4 2 3 3 5 2 38 5
3 7 4 4 4 4 2 3 2 5 1 36 4
4 5 3 4 4 3 3 4 3 4 1 34 3
5 6 4 4 5 4 3 4 4 5 1 40 6
6 7 6 6 5 6 4 5 5 7 2 53 9
7 6 5 5 4 4 3 4 5 6 1 43 8
8 6 5 4 5 4 3 4 4 6 1 42 7
9 6 3 3 4 3 2 3 3 4 1 32 2
10 8 6 7 7 7 6 7 7 7 4 66 10
4. Discussion
According to the results of the expert evaluation analysis, it can be argued that based on the 
ranking of the assessment of the importance of factors influencing the level of adaptive management 
of the MPhCo, the agreed opinion of all groups of experts can be represented as ranking priorities:
1. Introduction of innovative production technologies.
2. Updating the material and technical base and production processes of the MPhCo.
3. Optimization of work with suppliers.
4. Application of marketing and logistics tools.
5. State financial support for the pharmaceutical industry.
6. Quality and availability of domestic medicines.
7. Maintaining the human resources potential of the MPhCo.
8. Antimonopoly regulation.
9. Advertising, public relations, membership in associations.
10. Methodological support of patent work at enterprises and institutions in pharmaceutical 
industry.
The main areas of improving the adaptive management efficiency of the MPhCo are the 
following conceptual provisions:
– ability to react to projected changes in the environment and the application of relevant 
management approaches;
– solving the problems of uncertainty and manoeuvrability of the parameters of the enter-
prise in terms of its economic growth and development;
– considering the heterogeneity of elements in the development process;
– adequacy of decisions on the development and real state of the enterprise;
– multicriteria evaluation of the enterprise development efficiency;
– the possibility of formulating management criteria based on analytical conclusions and 
results of control and coordination of development processes [20].
However, taking into account the specifics of the pharmaceutical business and the peculia-
rities of the management organization in MPhCo, in our opinion, the main areas of improving the 
adaptive management efficiency are:
– development and implementation of the target program of enterprise development, which 
considered possible stochastic changes in the external environment;
– development and calculation of a system of indicators that adequately reflect the current 
(actual) and planned state of the enterprise and the external environment;
– system of goals formation (target functions of development) of the enterprise, which takes 
into account the need for strategic positioning in the external environment;
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– efficient use of material and intellectual resources;
– formation of a simulation model of adaptive management of the MPhCo, which is the basis
of the support system for management decisions;
– development of an algorithm for the practical use of the simulation model and the corre-
sponding organizational and technical support;
– continuous public relations of the enterprise;
– improvement of information and communication support of economic entities of the phar-
maceutical industry.
The listed directions of increase of adaptive management efficiency of MPhCo in practice 
will give pharmaceutical branch and the enterprises real opportunities of achievement a certain 
competitiveness level, reception of competitive advantages on indicators of the management level 
in modern economic conditions.
Thus, improving adaptive management in the formation of competitive advantages of the 
MPhCo requires businesses to be determined, flexible and adequate both in the formation of mo-
dern management strategies and in tactical planning and implementation of operational tasks for 
the current production and economic and commercial activities.
Study limitations. Missing research is possible only in a market-driven economy.
The prospect of further research should be to determine the current state and improve the 
quality of management decisions for the development of manufacturing pharmaceutical companies.
5. Conclusions
The directions of increasing the adaptive management efficiency are determined and it is 
concluded that the main criterion of efficiency is the quality of pharmaceutical products and the 
quality of management decisions in economic risks.
The study proved that these areas of improving the adaptive management effectiveness in 
MPhCo, in practice provide real opportunities for the pharmaceutical industry to achieve a certain 
level of competitiveness as pharmaceutical manufacturers and gain competitive advantage in terms 
of management.
It is noted that the improvement of adaptive management in forming of competitive ad-
vantages in the MPhCo should be considered in terms of the following factors of influence: 
socio-economic, organizational-economic, organizational-legal, organizational-technical, organi-
zational-technological.
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